Ultrasound Opens Blood-Brain Barrier: New Treatments
“`html
Focused Ultrasound Shows Promise in Delivering Chemotherapy Across the Blood-Brain Barrier
What Happened?
Researchers are reporting encouraging early results using focused ultrasound to temporarily open the blood-brain barrier (BBB), allowing chemotherapy drugs to reach brain tumors more effectively. Conventional chemotherapy struggles to penetrate the BBB,a protective mechanism that shields the brain from harmful substances but also blocks many life-saving medications. Recent studies, including those highlighted by medscape and News-Medical.net, demonstrate the potential of this non-invasive technique to improve treatment outcomes for patients wiht glioblastoma and other brain cancers.
How Does Focused Ultrasound Work?
Focused ultrasound uses precisely targeted sound waves to create temporary, localized openings in the blood-brain barrier. These openings are created by inducing microbubbles in the bloodstream, which oscillate and gently disrupt the tight junctions between cells that form the BBB. The effect is reversible, meaning the barrier reseals within hours, minimizing potential long-term risks.the process is guided by MRI, allowing doctors to visualize the opening and ensure accurate targeting of the tumor.
The Challenge of the Blood-Brain Barrier
The blood-brain barrier is a highly selective semipermeable border of endothelial cells that prevents solutes in the circulating blood from non-selectively entering the central nervous system, where they could cause damage. While crucial for protecting the brain, it presents a notable hurdle for delivering therapeutic agents. Only a small percentage (typically less than 2%) of chemotherapy drugs can cross the BBB in sufficient quantities to be effective. This limitation drastically reduces the efficacy of systemic chemotherapy for brain tumors.
| Drug | Typical BBB Penetration (%) |
|---|---|
| Methotrexate | 5-10% |
| Cisplatin | <1% |
| Doxorubicin | <1% |
Recent Research Findings
A recent phase 1 clinical trial at Sunnybrook Health Sciences Centre in Toronto showed that focused ultrasound, combined with chemotherapy